- Previous Close
2.4100 - Open
2.3300 - Bid --
- Ask --
- Day's Range
2.1200 - 2.3950 - 52 Week Range
1.9000 - 9.4000 - Volume
138,760 - Avg. Volume
1,611,357 - Market Cap (intraday)
3.539M - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2600 - Earnings Date Jun 16, 2025 - Jun 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.00
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
sonomapharma.com10
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SNOA
View MorePerformance Overview: SNOA
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNOA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNOA
View MoreValuation Measures
Market Cap
3.89M
Enterprise Value
-1.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.18
Price/Book (mrq)
0.80
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.82%
Return on Assets (ttm)
-19.72%
Return on Equity (ttm)
-64.83%
Revenue (ttm)
13.97M
Net Income Avi to Common (ttm)
-3.75M
Diluted EPS (ttm)
-2.2600
Balance Sheet and Cash Flow
Total Cash (mrq)
5.24M
Total Debt/Equity (mrq)
2.44%
Levered Free Cash Flow (ttm)
1.25M